BioCryst Pharmaceuticals surges 2% on strong Q1 results, raised outlook

Published 05/05/2025, 12:14
BioCryst Pharmaceuticals surges 2% on strong Q1 results, raised outlook

RESEARCH TRIANGLE PARK, N.C. - BioCryst Pharmaceuticals , Inc. (NASDAQ:BCRX) reported better-than-expected first quarter results and raised its full-year revenue guidance on Monday.

The company saw its shares jump up 2.13% in premarket trading after the earnings release.

The biotechnology company posted Q1 adjusted earnings of $0.00 per share, beating analyst estimates of a $0.07 per share loss. Revenue surged 51% YoY to $134.2 million, exceeding the consensus forecast of $127.91 million.

BioCryst’s ORLADEYO, an oral treatment for hereditary angioedema (HAE), drove the strong performance with Q1 net revenue of $134.2 million, up 51% from the same period last year.

"We started 2025 with another quarter of outstanding performance. ORLADEYO revenue growth was driven by moving ORLADEYO patients from free drug to paid at a much faster rate than we expected," said Jon Stonehouse, president and CEO of BioCryst.

The company raised its full-year 2025 ORLADEYO revenue guidance to $580-600 million, up from its previous outlook of $535-550 million and above analyst projections of $563.6 million.

BioCryst now expects to achieve profitability in 2025, a year ahead of schedule. The company also paid down $75 million of debt, which it says will save approximately $23.5 million over the life of the loan.

In pipeline news, BioCryst submitted a new drug application to expand ORLADEYO’s label to children with HAE aged 2 to 11. The company also opened a U.S. investigational new drug application for BCX17725 to treat Netherton syndrome.

BioCryst ended the quarter with $317.3 million in cash and investments.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.